January 23, 2024
The Second Circuit on Tuesday backed a ruling banning former pharmaceutical executive and convicted securities fraudster Martin Shkreli from the drug industry for life, saying a repeat of his past misconduct would be "life-threatening."
December 14, 2023
An attorney for former pharmaceutical executive and convicted securities fraudster Martin Shkreli asked a Second Circuit panel to lift a lifetime industry ban on his client, saying it steps on Shkreli's First Amendment rights and bars him from other, unrelated sectors.
July 20, 2023
The Federal Trade Commission and a group of state attorneys general told the Second Circuit on Thursday that Martin Shkreli can't cite a U.S. Supreme Court decision defining when speech is a "true threat" to overturn his lifetime pharmaceutical industry ban.
July 13, 2023
Martin Shkreli has told the Second Circuit his appeal of a lifetime pharmaceutical industry ban is bolstered by the U.S. Supreme Court's recent decision that courts must consider a speaker's intent when deciding what is a "true threat."
April 14, 2023
Martin Shkreli pressed the Second Circuit on Thursday to overturn his $64.6 million fine and lifetime pharmaceutical industry ban imposed through a Federal Trade Commission and attorneys general antitrust case, arguing the ban is overbroad and his company should be fined, not him.